Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Expert Review of Vaccines|June 27, 2014
The value of HIV protective epitope research for informed vaccine design against diverse viral pathogensVictor G Kramer, Siddappa N ByrareddyCurrent HIV Research|November 30, 2007
Passive immunization as tool to identify protective HIV-1 Env epitopesVictor G Kramer, Nagadenahalli B Siddappa, Ruth M RuprechtVirology Journal|October 8, 2014
Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell linesYudong Quan, Hongtao Xu, Victor G Kramer, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodiesVictor G Kramer, Olivia Varsaneux, Maureen Oliviera, et al.The Journal of Antimicrobial Chemotherapy|November 30, 2014
The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA declineVictor G Kramer, Said Hassounah, Susan P Colby-Germinario, et al.Journal of Medicinal Chemistry|December 6, 2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to ClinicVigneshwaran Namasivayam, Murugesan Vanangamudi, Victor G Kramer, et al.Vaccine|February 10, 2009
Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survivalSaied Mirshahidi, Victor G Kramer, James B Whitney, et al.Antimicrobial Agents and Chemotherapy|May 23, 2012
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral loadVictor G Kramer, Susan M Schader, Maureen Oliveira, et al.Antimicrobial Agents and Chemotherapy|July 17, 2013
Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptaseMatthew McCallum, Maureen Oliveira, Ruxandra-Ilinca Ibanescu, et al.Antiviral Chemistry & Chemotherapy|July 8, 2015
Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitorYing-Shan Han, Wei-Lie Xiao, Hongtao Xu, et al.Pageof 2